Lifeward Ltd LFWD

$5.85 -0.11 (-1.85%)

Valuation

Market cap
16,879,000
Revenue TTM
$22,030,000
Net income TTM
$-19,910,000
PE ratio
0.00
Forward PE
—
Profit margin
-90.38%
Debt to equity
0.33

Trading

Volume
6,100
Avg volume
5,464
Day's range
$5.85 – $6.35
Shares out
2,832,000
Stochastic %K
34%
Beta
0.47
Analysts
Sell
Price target
$10.00

Price

Company profile

Lifeward Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, Germany, the Asia-Pacific, and internationally. It offers ReWalk personal exoskeleton and rehabilitation exoskeleton devices for individuals with spinal cord injury; ReStore...

Show more

Lifeward Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, Germany, the Asia-Pacific, and internationally. It offers ReWalk personal exoskeleton and rehabilitation exoskeleton devices for individuals with spinal cord injury; ReStore Exo-Suit, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke; AlterG Anti-Gravity System for use in physical and neurological rehabilitation and athletic training; MyoCycle devices; and ReBoot, a personal soft exo-suit for home and community use by individuals' post-stroke. The company markets and sells its products directly to institutions and individuals, as well as through third-party distributors. The company was formerly known as ReWalk Robotics Ltd. and changed its name to Lifeward Ltd. in September 2024. Lifeward Ltd. was incorporated in 2001 and is based in Yokneam Illit, Israel.

Industry
Medical Devices
Sector
Healthcare
Phone
972 4 959 0123
Website
https://golifeward.com
Address
3 Hatnufa St., 6th floor P.O. Box 161, Yokneam Illit, Israel

Latest news

No headlines yet.